Tocilizumab in MOG-antibody spectrum disorder: a case report

G Novi, M Gastaldi, D Franciotta, G Pesce, L Benedetti, A Uccelli

Research output: Contribution to journalArticlepeer-review


BACKGROUND: Myelin oligodendrocyte glycoprotein antibody-related spectrum disorders (MOG-SD) are a heterogeneous group of inflammatory demyelinating diseases of the central nervous system, usually responsive to conventional immunosuppressive therapies. However, knowledge about treatment of non-responder patients is scarce.

METHODS: We report on a 20-year-old MOG-SD patient who experienced clinical deterioration despite rituximab-induced B-cell depletion.

RESULTS: Rescue therapy with tocilizumab (TCZ) prevented further relapses, with reduction of spinal-cord load on MRI, and a remarkable reduction of disability at the two-year follow-up.

CONCLUSION: Our observations suggest that TCZ could induce clinico-radiologic improvements, which make it as an option for the treatment of MOG-SD.

Original languageEnglish
Pages (from-to)312-314
Number of pages3
JournalMultiple Sclerosis and Related Disorders
Publication statusE-pub ahead of print - Nov 13 2018


Dive into the research topics of 'Tocilizumab in MOG-antibody spectrum disorder: a case report'. Together they form a unique fingerprint.

Cite this